

Nicotine Addiction - Pipeline Review, H2 2019

<https://marketpublishers.com/r/N955921E4BDEN.html>

Date: November 2019

Pages: 76

Price: US\$ 2,000.00 (Single User License)

ID: N955921E4BDEN

Abstracts

Nicotine Addiction - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nicotine Addiction - Pipeline Review, H2 2019, provides an overview of the Nicotine Addiction (Central Nervous System) pipeline landscape.

Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post-traumatic stress disorder and alcoholism. Person experiences withdrawal symptoms at cessation of using, such as shaky hands, sweating, irritability, or rapid heart rate. Treatment includes nicotine replacement therapy (NRT).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nicotine Addiction - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Nicotine Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nicotine Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II,

Phase I, Preclinical and Discovery stages are 1, 3, 18 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 5 molecules, respectively.

Nicotine Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Nicotine Addiction (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Nicotine Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Nicotine Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Nicotine Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of

administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Nicotine Addiction (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Nicotine Addiction (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Nicotine Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Nicotine Addiction - Overview
- Nicotine Addiction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Nicotine Addiction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Nicotine Addiction - Companies Involved in Therapeutics Development
- Antidote Therapeutics Inc
- Assuage Pharmaceuticals Inc
- Astraea Therapeutics LLC
- Avicanna Inc
- Camino Pharma LLC
- Cessation Therapeutics LLC
- Chronos Therapeutics Ltd
- CV Sciences Inc
- DemeRx Inc
- EncepHeal Therapeutics Inc
- Eolas Therapeutics Inc
- Indivior Plc
- MAKScientific LLC
- Mind Medicine Inc
- Molecular Express Inc
- Omeros Corp
- Palisades Therapeutics
- Sosei Heptares
- Sunomix Therapeutics
- Tria Bioscience Corp
- Nicotine Addiction - Drug Profiles
- (cannabidiol + nicotine) - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
18-MC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-4113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-6527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-1013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-3009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-4X3256 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Fusion Protein for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Noribogaine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

psilocybin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PT-150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBP-0069330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CB1 and Agonize CB2 for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Neurology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize HCRTR1 for Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URB-694 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nicotine Addiction - Dormant Projects

Nicotine Addiction - Discontinued Products

Nicotine Addiction - Product Development Milestones

Featured News & Press Releases

Aug 05, 2019: Antidote Therapeutics progresses optimization of the nicotine-degrading enzyme, NicA2, for potential use in treating nicotine addiction

Jul 20, 2017: CV Sciences Cites Recent Clinical Study on Pharmaceutical-Grade CBD Shown to Lower Blood Pressure

Jul 11, 2017: CV Sciences Appoints Dr. Amy M. McCord as Director of Drug Development

Jun 19, 2017: CV Sciences Announces Commencement of IND preparation immediately following Pre-IND Meeting With FDA

May 02, 2017: CV Sciences Announces Pre-IND Meeting Date with FDA

May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development

Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction

Feb 16, 2012: Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine

May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Nicotine Addiction, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Nicotine Addiction - Pipeline by Antidote Therapeutics Inc, H2 2019
Nicotine Addiction - Pipeline by Assuage Pharmaceuticals Inc, H2 2019
Nicotine Addiction - Pipeline by Astraea Therapeutics LLC, H2 2019
Nicotine Addiction - Pipeline by Avicanna Inc, H2 2019
Nicotine Addiction - Pipeline by Camino Pharma LLC, H2 2019
Nicotine Addiction - Pipeline by Cessation Therapeutics LLC, H2 2019
Nicotine Addiction - Pipeline by Chronos Therapeutics Ltd, H2 2019
Nicotine Addiction - Pipeline by CV Sciences Inc, H2 2019
Nicotine Addiction - Pipeline by DemeRx Inc, H2 2019
Nicotine Addiction - Pipeline by EncepHeal Therapeutics Inc, H2 2019
Nicotine Addiction - Pipeline by Eolas Therapeutics Inc, H2 2019
Nicotine Addiction - Pipeline by Indivior Plc, H2 2019
Nicotine Addiction - Pipeline by MAKScientific LLC, H2 2019
Nicotine Addiction - Pipeline by Mind Medicine Inc, H2 2019
Nicotine Addiction - Pipeline by Molecular Express Inc, H2 2019
Nicotine Addiction - Pipeline by Omeros Corp, H2 2019
Nicotine Addiction - Pipeline by Palisades Therapeutics, H2 2019
Nicotine Addiction - Pipeline by Sosei Heptares, H2 2019
Nicotine Addiction - Pipeline by Sunomix Therapeutics, H2 2019
Nicotine Addiction - Pipeline by Tria Bioscience Corp, H2 2019
Nicotine Addiction - Dormant Projects, H2 2019
Nicotine Addiction - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Nicotine Addiction, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019

COMPANIES MENTIONED

Antidote Therapeutics Inc
Assuage Pharmaceuticals Inc
Astraea Therapeutics LLC
Avicanna Inc
Camino Pharma LLC
Cessation Therapeutics LLC
Chronos Therapeutics Ltd
CV Sciences Inc
DemeRx Inc
EncepHeal Therapeutics Inc
Eolas Therapeutics Inc
Indivior Plc
MAKScientific LLC
Mind Medicine Inc
Molecular Express Inc
Omeros Corp
Palisades Therapeutics
Sosei Heptares
Sunomix Therapeutics
Tria Bioscience Corp

I would like to order

Product name: Nicotine Addiction - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/N955921E4BDEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N955921E4BDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970